## ONE NORTH CAROLINA SMALL BUSINESS PROGRAM COMPANIES ADDRESSING COVID-19

The One North Carolina Small Business Program helps small, innovation-based companies bring new technologies to commercialization by matching federal Phase I Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) grants.

More Information on the One North Carolina Small Business Program is found at: <a href="nccommerce.com/sti/grant-programs/one-nc-small-business-program">nccommerce.com/sti/grant-programs/one-nc-small-business-program</a>.



These companies develop technologies across a wide array of industries, and six companies are developing testing and diagnostic technologies, treatments, or other products for addressing COVID-19. The six companies have received ten One NC Small Business Program grants (totaling \$587,000) and currently employ 119 people. The companies are:



Asklepios BioPharmaceutical, Inc. (AskBio) is a clinical-stage adeno-associated virus (AAV) gene therapy company dedicated to improving the lives of patients with rare diseases and other genetic disorders. AskBio is working on a vectorized antibody approach to address COVID-19 using its adeno-associated virus (AAV) platform.



<u>BioMedomics, Inc.</u> is a point-of-care diagnostics company that aims to provide novel, rapid point-of-care tests to aid in the diagnosis of critical diseases. BioMedomics has developed and launched one of the world's first rapid point-of-care lateral flow immunoassays for the diagnosis of coronavirus infection.



<u>Collaborations Pharmaceuticals, Inc.</u> works on drug discovery for rare and neglected diseases. Collaborations Pharmaceuticals has its Assay Central machine-learning software for building models to predict compounds with likely activity against the Coronavirus.

## Mucomunne

**Mucommune, LLC** researches improved protection against infectious diseases transmitted at mucosal surfaces. Inhalon Biopharma, a spin-off from Mucommune, is advancing inhaled, muco-trapping therapeutics for treatment of COVID-19.



**Novan, Inc.** uses a proprietary nitric oxide-based science and technology platform to develop innovative, first-in-class therapies for unmet medical needs. Novan's nitric-oxide platform may have potential as a treatment for COVID-19, as it has the ability to inhibit viral replication.



<u>Plasma Games, Inc.</u> formerly known as Athena's Compass, LLC, Plasma Games develops entertainment-quality video games for STEM classes. Plasma Game donated its National Science Foundation award-winning resource, Sci-Ops: Global Defense, to teachers across the US to help during this COVID-19 crisis.

